Updated on 22 August 2013
Big pharma's rising interest in emerging markets is expected to further squeeze the profitability of India's generics manufacturers, particularly that of smaller firms. Major players from Europe, Asia, and North America are investing significantly in India and taking advantage of the nation's relatively cheap resources.
While this interest will inevitably put pressure on India's domestic firms, it will also play a key role in driving the country's pharmaceutical market value. Furthermore, the revenue is estimated to increase from $17 billion in 2012 to $54 billion in 2020.